Evidence map›Paper›PMID 40124024›Full record

ArticleACS omega2025

Application of Gelatin/Vanillin/Fe

Sarawut Lapmanee, Sakkarin Bhubhanil, Mattaka Khongkow, Katawut Namdee, Werayut Yingmema, Narumol Bhummaphan, Prapimpun Wongchitrat, Natthawut Charoenphon, James A Hutchison, Chanon Talodthaisong and 1 more

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarawut LapmaneeChulabhorn International College of Medicine, Thammasat University, Pathumthani 10120, Thailand.ORCID https://orcid.org/0000-0002-8890-9109
Sakkarin BhubhanilDepartment of Basic Medical Sciences, Faculty of Medicine, Siam University, Bangkok 10160, Thailand.
Mattaka KhongkowNational Science and Technology Development Agency, National Nanotechnology Centre, Pathumthani 12120, Thailand.ORCID https://orcid.org/0000-0002-4424-8898
Katawut NamdeeNational Science and Technology Development Agency, National Nanotechnology Centre, Pathumthani 12120, Thailand.ORCID https://orcid.org/0000-0003-3763-9388
Werayut YingmemaLaboratory Animal Center, Thammasat University, Pathumthani 10120, Thailand.
Narumol BhummaphanCollege of Public Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Prapimpun WongchitratCenter for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Nakhon Pathom 73170, Thailand.
Natthawut CharoenphonDepartment of Anatomy, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.
James A HutchisonSchool of Chemistry and Centre of Excellence in Exciton Science, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID https://orcid.org/0000-0002-0595-9961
Chanon TalodthaisongDepartment of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002, Thailand.
Sirinan KulchatDepartment of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID https://orcid.org/0000-0002-2411-7495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study further investigates the potential of gelatin-based hydrogel cross-linked with vanillin and ferric ion (GVF), combined with andrographolide (AGP) and silver nanoparticles (AgNPs), as an anti-infection biomaterial for wound dressing, aimed at exploring the mechanisms that attenuate inflammation, enhance wound healing rates, and address allergic skin irritation. AGP-AgNPs were evaluated for cytotoxicity in human adult epidermal keratinocytes (HEKa) and the murine macrophage cell line (RAW 264.7), as well as for nitric oxide (NO) production in response to lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells. Skin-wound specimens from male Wistar rats were histologically analyzed for epidermal thickness and inflammatory changes. The mRNA expression profiling of dermal growth factors was assessed using RT-qPCR, and skin irritation tests were conducted in female New Zealand rabbits. These AGP-AgNPs exhibited significantly lower toxicity in HEKa and no toxicity in RAW 264.7. Interestingly, AGP-AgNPs at specific concentrations produced NO in RAW 264.7 control cells but were more effective in reducing inflammatory NO levels in RAW 264.7 cells pretreated with lipopolysaccharides, suggesting that AGP-AgNP composites are safe and effectively diminish inflammation. Furthermore, a marked increase in epidermal thickness and a reduction in histological inflammatory cells at wound sites were observed in rats treated with AGP-AgNPs/GVF hydrogels over 21 days. Upregulation of dermal genes promoting wound healing, including collagen types I and III, epidermal growth factor, transforming growth factor-beta, fibronectin, and vascular endothelial growth factor, but not fibroblast growth factor, was observed in a time-dependent manner. These results suggest that the anti-inflammatory properties of GVF/AGP-AgNP hydrogels could promote epithelialization, enhance cellular proliferation, support extracellular matrix synthesis, and facilitate angiogenesis. Additionally, rabbit skin in contact with GVF/AGP-AgNP hydrogels consistently displayed reduced levels of erythema and edema, with no swelling, and a standardized scoring system yielded low primary dermal irritation indices for this hydrogel. These findings suggest that the novel GVF/AGP-AgNP hydrogels possess anti-inflammatory-like activity and can modulate dermal growth factors for wound healing. This leads to reduced dermal irritation, making the formulation potentially suitable for safe topical applications in skin and wound care. However, comprehensive human studies and clinical trials should be required in the future.

Identifiers

PMID40124024
PMCPMC11923657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.